Search
Displaying 611–620 of 938 results for “vision connection”
-
Belite Bio Submits New Drug Application to FDA for its Stargardt Treatment
Research NewsTinlarebant becomes first Stargardt treatment submitted to FDA for approval
-
Foundation News
The award recognizes Dr. Pierce’s contributions to inherited retinal disease research, including work that led to the first FDA-approved gene therapy for an inherited disease and leadership of the world’s first in vivo CRISPR genome-editing study in humans.
-
Sumitomo Pharma Receives FDA Orphan Drug Designation for Retinitis Pigmentosa Treatment
Research NewsPotential cell therapy, DSP-3077, gains special regulatory status to support development for inherited retinal disease.
-
Foundation News
The May 14 event will convene leaders across industries to raise funds that advance treatments and cures for blinding diseases.
-
Eye on the Cure Podcast | Episode 98: Jonathan & Josh Steinberg
Eye on the CureJosh Steinberg and his father, Jon, talk with host Ben Shaberman about their close-knit family’s journey with Josh’s vision loss.
-
RD Fund Invests in Beacon Therapeutics to Advance XLRP Gene Therapy
Research NewsThe venture philanthropy arm of the Foundation partnered with other investors to support the development of a gene therapy trial for X-linked retinitis pigmentosa (XLRP).
-
Belite Bio to Seek FDA Approval for its Stargardt Disease Drug
Research NewsTinlarebant slowed disease progression by 36 percent in the Dragon Phase 3 clinical trial.
-
Opus Genetics Launches Gene Therapy Clinical Trial for Best Disease
Research NewsThe Foundation funded preclinical studies for the approach and launched Opus.
-
Sepul Bio’s LCA10 RNA Therapy Moves into Phase 3 Clinical Trial
Research NewsThe emerging therapy improved vision for some participants in an earlier clinical trial.
-
Letter to House Energy & Commerce Committee regarding H.R.1262, the Give Kids a Chance Act.
Advocacy Research NewsOn behalf of the Foundation Fighting Blindness and the millions of Americans impacted by inherited retinal diseases (IRDs), we urge you to advance H.R.1262, the Give Kids a Chance Act, and reauthorize the Rare Pediatric Disease Priority Review Voucher (PRV) Program.
